Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

medRxiv logoLink to medRxiv
[Preprint]. 2024 Jan 13:2024.01.12.24301242. [Version 1] doi: 10.1101/2024.01.12.24301242

Systematic proteomics in Autosomal dominant Alzheimer’s disease reveals decades-early changes of CSF proteins in neuronal death, and immune pathways

Yuanyuan Shen, Muhammad Ali, Jigyasha Timsina, Ciyang Wang, Anh Do, Daniel Western, Menghan Liu, Priyanka Gorijala, John Budde, Haiyan Liu, Brian Gordon, Eric McDade, John C Morris, Jorge J Llibre-Guerra, Randall J Bateman, Nelly Joseph-Mathurin, Richard J Perrin, Dario Maschi, Tony Wyss-Coray, Pau Pastor, Alison Goate, Alan E Renton, Ezequiel I Surace, Erik C B Johnson, Allan I Levey, Ignacio Alvarez, Johannes Levin, John M Ringman, Ricardo Francisco Allegri, Nicholas Seyfried, Gregg S Day, Qisi Wu, M Victoria Fernández; Dominantly Inherited Alzheimer Network, Laura Ibanez, Yun Ju Sung, Carlos Cruchaga
PMCID: PMC10802763  PMID: 38260583

Abstract

Background

To date, there is no high throughput proteomic study in the context of Autosomal Dominant Alzheimer’s disease (ADAD). Here, we aimed to characterize early CSF proteome changes in ADAD and leverage them as potential biomarkers for disease monitoring and therapeutic strategies.

Methods

We utilized Somascan® 7K assay to quantify protein levels in the CSF from 291 mutation carriers (MCs) and 185 non-carriers (NCs). We employed a multi-layer regression model to identify proteins with different pseudo-trajectories between MCs and NCs. We replicated the results using publicly available ADAD datasets as well as proteomic data from sporadic Alzheimer’s disease (sAD). To biologically contextualize the results, we performed network and pathway enrichment analyses. Machine learning was applied to create and validate predictive models.

Findings

We identified 125 proteins with significantly different pseudo-trajectories between MCs and NCs. Twelve proteins showed changes even before the traditional AD biomarkers (Aβ42, tau, ptau). These 125 proteins belong to three different modules that are associated with age at onset: 1) early stage module associated with stress response, glutamate metabolism, and mitochondria damage; 2) the middle stage module, enriched in neuronal death and apoptosis; and 3) the presymptomatic stage module was characterized by changes in microglia, and cell-to-cell communication processes, indicating an attempt of rebuilding and establishing new connections to maintain functionality. Machine learning identified a subset of nine proteins that can differentiate MCs from NCs better than traditional AD biomarkers (AUC>0.89).

Interpretation

Our findings comprehensively described early proteomic changes associated with ADAD and captured specific biological processes that happen in the early phases of the disease, fifteen to five years before clinical onset. We identified a small subset of proteins with the potentials to become therapy-monitoring biomarkers of ADAD MCs.

Funding

Proteomic data generation was supported by NIH: RF1AG044546

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from medRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES